𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Medroxyprogesterone acetate bioavailability after high-dose intraperitoneal administration in advanced cancer

✍ Scribed by Carlo M. Camaggi; Elena Strocchi; Barbara Costanti; Paola Beghelli; Patrizio Ferrari; Franco Pannuti

Publisher
Springer
Year
1985
Tongue
English
Weight
273 KB
Volume
14
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

✦ Synopsis

Administration of medroxyprogesterone acetate IP in advanced cancer with peritoneal metastases and ascitic effusion generates considerably higher drug plasma levels than those observed after PO or IM treatment. Comparison of areas under the time-concentration curves (AUC) with reference to the three administration routes indicates that after oral administration only 0.2%-17.4% (mean 5.7%; SD 3.77; 40 patients) of the administered dose is absorbed; after IM treatment a daily absorption of 0.7%-7.7% (mean 2.5%; SD 1.66; 30 patients) of the administered dose per injection site was computed.

πŸ“œ SIMILAR VOLUMES

Medroxyprogesterone acetate (MAP) plasma
Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administration in advanced cancer patients
✍ Carlo Maurizio Camaggi; Elena Strocchi; Michele Giovannini; Bruna Angelelli; Bar πŸ“‚ Article πŸ“… 1983 πŸ› Springer 🌐 English βš– 352 KB

Medroxyprogesterone acetate plasma levels were measured in advanced cancer patients after multiple PO or IM administration (500, 1000, 2000, 3000, 4000, and 5000 mg/day PO and 500, 1000, 2000 mg/day IM for 30 days). After PO administration, the plasma concentration rises quickly and plateau level is

A phase II study of high-dose medroxypro
A phase II study of high-dose medroxyprogesterone acetate in advanced breast cancer
✍ Geoffrey Falkson; HΓ¨ndrΓ© C. Falkson πŸ“‚ Article πŸ“… 1983 πŸ› Springer 🌐 English βš– 215 KB

Twenty-three evaluable patients with advanced breast cancer were treated with MPA, 1,400 mg/m2 daily PO for the first 6 months, and 500 mg/m2 daily PO thereafter. The median total dose was 191,400 mg in 88 days, with the maximum dose given to date 522,600 mg in 282 days. Most patients tolerated high

Adrenal suppression by oral high-dose me
Adrenal suppression by oral high-dose medroxyprogesterone acetate in breast cancer patients
✍ Henk Veelen; Pax H. B. Willemse; Dirk T. Sleijfer; John J. Pratt; Wim J. Sluiter πŸ“‚ Article πŸ“… 1984 πŸ› Springer 🌐 English βš– 332 KB

The effects of oral MPA, 300 mg t.i.d., on adrenal function in postmenopausal patients with disseminated breast cancer were evaluated. The levels of serum cortisol, ACTH, androstenedione, DHEA-S, LH, FSH, GH, and prolactin in 22 patients receiving MPA were compared with those in another group of 28

Medroxyprogesterone acetate (MAP) plasma
Medroxyprogesterone acetate (MAP) plasma levels after simultaneous oral and intramuscular administration in cancer patients
✍ Franco Pannuti; Carlo Maurizio Camaggi; Elena Strocchi; Michele Giovannini; Nadi πŸ“‚ Article πŸ“… 1982 πŸ› Springer 🌐 English βš– 141 KB

After simultaneous administration of medroxyprogesterone acetate (MAP) 1,000 mg PO and 1,000 mg IM to ten cancer patients, we observed mean plasma MAP profiles that could be exactly superimposed on the two absorption/decay curves obtained after administration of single doses IM or PO. Treatment with